Another AmerisourcBergen acquisition; IntrinsiQ for $35m

By Gareth Macdonald

- Last updated on GMT

Related tags Chemotherapy

AmerisourceBergen has bought informatics firm IntrinsiQ for $35m (€25m) continuing the spending spree it began earlier this week with the acquisition of market access consultancy Premier Source.

Burlington, Massachusetts-based IntrinsiQ collects ‘real world’ prescribing and treatment data from oncology clinical using its IntelliDose software platform and provides it to pharmaceutical firms and physicians to ‘improve patient health outcomes.

The software firm will become part of AmerisourceBergen’s ION Solutions unit, whose core business is the provision of clinical, practice management and reimbursement tools to help oncologists make the correct clinical dosing decisions.

According to IntrinsiQ's website the firm works with a range of companies in the pharmaceutical sector, including contract research organisations (CRO) like PRA International and eClinicalWorks, GE Healthcare's ambulatory services unit Centricity and market analyst IMS Health.

AmerisourceBergen said: “The combination of IntrinsiQ's software applications and ION Solutions' existing oncology technology platform will enhance the Company's proprietary data offerings to both physicians and manufacturers.”

The acquisition is the second time AmerisourceBergen has dipped into its $1.2bn (€1.4bn) cash reserve this week and is a continuation of its efforts to diversify its contract services offering.


AmerisourceBergen set out its acquisition plans shortly after predicted that sales of key products – namely the cancer drugs oxaliplatin, gemcitabine and docetaxel which are sold by its contract distribution business - would ‘moderate’ in coming quarters.

This fits with analysis by Zacks Investment Research​ who predicted that although AmerisourceBergen had benefitted from the higher sales of the three products in the first half of the year, the situation would not be the same in the remainder of 2011.

The company is out of stock of oxaliplatin and the drug will not be available before the fourth quarter of fiscal 2012. Additionally, contributions from gemcitabine and docetaxel will also come down as more manufacturers with the generic drug enter the market and reimbursement rates decline​.”

AmerisourceBergen did not respond to’s request for additional information.

Related news

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more